MoonLake Immunotherapeutics (MLTX) Operating Expenses (2021 - 2026)

MoonLake Immunotherapeutics' Operating Expenses history runs 6 years deep, the most recent figure standing at $70.0 million for Q1 2026.

• On a quarterly basis, Operating Expenses rose 47.47% year-over-year to $70.0 million in Q1 2026; TTM through Mar 2026 was $267.4 million, a 56.58% increase from a year earlier, with the FY2025 full-year figure at $244.8 million, up 71.1% from the prior year.
• Operating Expenses advanced to $70.0 million in Q1 2026 per MLTX's latest filing, from $65.2 million in the prior quarter.
• Across five years, Operating Expenses topped out at $71.4 million in Q3 2025 and bottomed at $12.9 million in Q1 2023.
• The 5-year median for Operating Expenses is $19.8 million (2024), against an average of $33.9 million.
• Biggest YoY gain for Operating Expenses was 16840.81% in 2022; the steepest drop was 68.84% in 2022.
• Year by year, Operating Expenses stood at $16.7 million in 2022, then dropped by 9.99% to $15.0 million in 2023, then jumped by 229.9% to $49.6 million in 2024, then soared by 31.54% to $65.2 million in 2025, then gained by 7.37% to $70.0 million in 2026.
• Per Business Quant, the three latest MLTX Operating Expenses figures stand at $70.0 million (Q1 2026), $65.2 million (Q4 2025), and $71.4 million (Q3 2025).